Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of E7386 and Lenvatinib for Patients with Liver, Colon, Endometrial, or Other Solid Tumors

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for people with different types of solid tumors, which are abnormal masses of tissue that can occur in various parts of the body. The specific types of cancer being studied include hepatocellular carcinoma (a type of liver cancer), colorectal cancer (cancer of the colon or rectum), and endometrial cancer (cancer of the lining of the uterus), among others. The treatment being tested involves a combination of a new drug called E7386 and another anticancer medication known as Lenvima (lenvatinib). E7386 is taken in the form of a tablet, while Lenvima is provided as hard capsules.

The purpose of this study is to evaluate the safety and tolerability of E7386 when used with other anticancer drugs and to determine the best dose for future studies. Participants in the trial will receive the study medications over a period of up to 26 weeks. The study will monitor how the body responds to the treatment and any side effects that may occur. Participants will take the medications orally, meaning they will swallow them, and will be regularly checked by the study team to ensure their safety and to track the progress of their treatment.

Throughout the study, researchers will collect information on how well the treatment works in controlling the cancer, including measuring the size of the tumors and checking for any signs of cancer progression. The study will also look at how long participants live after starting the treatment and how long any positive effects of the treatment last. This information will help determine if the combination of E7386 and Lenvima is a promising option for treating solid tumors in future clinical trials.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant will be informed about the trial's purpose, which is to assess the safety and tolerability of the drug E7386 in combination with other anticancer drugs.

    The participant will be required to provide informed consent, acknowledging understanding of the study's procedures and potential risks.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm eligibility, including a review of medical history and current health status.

    The participant must have a confirmed diagnosis of a solid tumor, such as hepatocellular carcinoma, colorectal cancer, or endometrial cancer, and meet specific health criteria.

  3. Step 3

    Treatment phase

    The participant will begin treatment with E7386 and Lenvima (lenvatinib).

    The dosage for Lenvima will be either 10 mg or 4 mg, administered orally in the form of hard capsules.

    The treatment will continue as prescribed by the study protocol, with regular monitoring to assess the participant's response and any side effects.

  4. Step 4

    Monitoring and follow-up

    Throughout the study, the participant will undergo regular check-ups to monitor health status and the effectiveness of the treatment.

    These check-ups will include physical examinations, imaging tests, and laboratory tests to evaluate the progression of the disease and any adverse effects.

  5. Step 5

    Completion of the study

    Upon completion of the study, the participant will have a final assessment to determine the overall impact of the treatment.

    The study aims to conclude by January 31, 2025, with results contributing to the understanding of the drug's safety and effectiveness.

Who can join the trial?

20 criteria

  • Patients must have a confirmed diagnosis of one of the following: hepatocellular carcinoma (HCC), colorectal cancer (CRC), endometrial cancer (EC), or another solid tumor.
  • For HCC patients: The cancer must be unresectable (cannot be removed by surgery) and confirmed by tests or clinical criteria.
  • For other solid tumor patients: The cancer must be confirmed by tests, and there should be no other standard or effective treatment options available.
  • Patients must have adequate liver function, meaning the liver is working well enough.
  • Patients must have adequate serum mineral levels, which means the minerals in the blood are at healthy levels.
  • Patients must have at least one measurable lesion (an area of cancer that can be measured) that meets specific size criteria.
  • For HCC patients: Must have a Child-Pugh score A, which is a way to assess liver function.
  • For HCC patients: Must be in stage B or C according to a specific liver cancer staging system.
  • For HCC patients in the expansion part: Must have had prior systemic therapy for advanced disease, with specific conditions on previous treatments.
  • For CRC patients in the expansion part: Must have had at least 2 prior treatment regimens and specific prior therapies if available.
  • For EC patients in the expansion part: Must show disease progression after prior systemic therapy and have received specific treatments.
  • Patients must have a life expectancy of at least 12 weeks.
  • Patients must have an ECOG performance status of 0-1, which measures daily living abilities.
  • All side effects from previous cancer treatments must have improved to a certain level, except for hair loss or mild nerve damage.
  • There must be an adequate washout period (time without treatment) before starting the study drug, depending on the type of previous treatment.
  • Patients must have adequately controlled blood pressure.
  • Patients must have adequate renal function, meaning the kidneys are working well enough.
  • Patients must have adequate bone marrow function, meaning the bone marrow is producing enough blood cells.
  • Both male and female patients are eligible.
  • Patients must be within the specified age range for the study.

Who cannot join the trial?

4 criteria

  • Patients with certain types of cancer, such as hepatocellular carcinoma (a type of liver cancer), colorectal cancer (cancer of the colon or rectum), endometrial cancer (cancer of the lining of the uterus), or other solid tumors, may not be eligible.
  • Patients who are not within the specified age range for the study may be excluded.
  • Patients who are part of a vulnerable population, which means they might need special protection or care, may not be eligible.
  • Patients who do not meet the safety and tolerability requirements for the study may be excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

E7386 is an investigational medication being studied for its potential use in treating solid tumors. It is part of a clinical trial to evaluate its safety and how well it is tolerated when used in combination with other cancer treatments. The goal is to find the best dose to use in future studies.

What is already known about the treatment

E7386 – E7386 is an investigational medication currently being studied in clinical trials for its potential use in treating various solid tumors, including hepatocellular carcinoma, colorectal cancer, and endometrial cancer. It is administered orally, allowing for convenient dosing. The medication is in the early stages of clinical research, specifically in a Phase 1b trial, where its safety and tolerability are being evaluated to determine the appropriate dose for further studies. E7386 works by targeting specific molecular pathways involved in cancer cell growth and survival, aiming to inhibit tumor progression. It is classified as an anticancer agent, and its development is focused on enhancing treatment options for patients with challenging cancer types.

Investigated diseases

  • Hepatocellular carcinoma

    This is the most common type of primary liver cancer, originating in the liver cells known as hepatocytes. It often develops in the context of chronic liver disease, such as cirrhosis or hepatitis. The disease may initially present with symptoms like abdominal pain, weight loss, or jaundice. As it progresses, the tumor can grow and spread to other parts of the body, potentially affecting liver function and overall health.

  • Colorectal cancer

    This cancer begins in the colon or rectum, parts of the large intestine, and is often grouped together due to their similarities. It typically starts as a growth called a polyp on the inner lining of the colon or rectum, which can become cancerous over time. Symptoms may include changes in bowel habits, blood in the stool, and abdominal discomfort. As the cancer advances, it can invade deeper layers of the colon or rectum and spread to other organs.

  • Endometrial cancer

    This type of cancer originates in the lining of the uterus, known as the endometrium. It is most commonly diagnosed in postmenopausal women and often presents with abnormal uterine bleeding. The cancer can grow and invade the muscular layer of the uterus and beyond. If not detected early, it may spread to other parts of the body, affecting overall health.

  • Other solid tumors

    This term refers to a diverse group of cancers that form solid masses in various organs or tissues, excluding blood cancers. These tumors can arise in different parts of the body, such as the lungs, pancreas, or kidneys. The progression of solid tumors varies widely depending on their location, type, and growth rate. Symptoms and effects on the body depend on the tumor's size, location, and whether it has spread to other areas.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-510275-64-00Protocol codeE7386-J081-102Estimated enrolment348 patientsSponsorEisai Limited

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.